These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37947758)

  • 1. Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis.
    Muthukumaraswamy SD
    Expert Rev Clin Pharmacol; 2023; 16(12):1163-1173. PubMed ID: 37947758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blinding and expectancy confounds in psychedelic randomized controlled trials.
    Muthukumaraswamy SD; Forsyth A; Lumley T
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1133-1152. PubMed ID: 34038314
    [No Abstract]   [Full Text] [Related]  

  • 3. Expectancy in placebo-controlled trials of psychedelics: if so, so what?
    Butler M; Jelen L; Rucker J
    Psychopharmacology (Berl); 2022 Oct; 239(10):3047-3055. PubMed ID: 36063208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncovering psychological mechanisms mediating the effects of drugs: some issues and comments using the example of psychedelic drugs.
    Kangaslampi S
    Psychopharmacology (Berl); 2020 Dec; 237(12):3799-3802. PubMed ID: 33151375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials.
    Schenberg EE
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1317-1319. PubMed ID: 34227438
    [No Abstract]   [Full Text] [Related]  

  • 8. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.
    Aday JS; Heifets BD; Pratscher SD; Bradley E; Rosen R; Woolley JD
    Psychopharmacology (Berl); 2022 Jun; 239(6):1989-2010. PubMed ID: 35359159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.
    Kious B; Schwartz Z; Lewis B
    J Psychopharmacol; 2023 Jan; 37(1):45-48. PubMed ID: 36377548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.
    Hovmand OR; Poulsen ED; Arnfred S; Storebø OJ
    J Psychopharmacol; 2023 Jul; 37(7):649-659. PubMed ID: 37403379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review.
    Nayak SM; Bradley MK; Kleykamp BA; Strain EC; Dworkin RH; Johnson MW
    J Clin Psychiatry; 2023 May; 84(3):. PubMed ID: 37167563
    [No Abstract]   [Full Text] [Related]  

  • 12. Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.
    Jing X; Hoeh NR; Menkes DB
    Palliat Support Care; 2023 Aug; 21(4):697-704. PubMed ID: 37334486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The need for establishing best practices and gold standards in psychedelic medicine.
    Feduccia A; Agin-Liebes G; Price CM; Grinsell N; Paradise S; Rabin DM
    J Affect Disord; 2023 Jul; 332():47-54. PubMed ID: 37003433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelic medicines for mood disorders: current evidence and clinical considerations.
    Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D
    Curr Opin Psychiatry; 2022 Jan; 35(1):22-29. PubMed ID: 34855694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?
    Feys F; Bekkering GE; Singh K; Devroey D
    Syst Rev; 2014 Feb; 3():14. PubMed ID: 24555576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing the Future of Psychedelics for Mental Health.
    Allen S
    IEEE Pulse; 2021; 12(4):6-10. PubMed ID: 34375272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.